Evidence map›Paper›PMID 30919133›Full record

ArticleEJNMMI research2019

Optimized dual-time-window protocols for quantitative [

Fiona Heeman, Maqsood Yaqub, Isadora Lopes Alves, Kerstin Heurling, Johannes Berkhof, Juan Domingo Gispert, Santiago Bullich, Christopher Foley, Adriaan A Lammertsma, AMYPAD Consortium

Abstract read
In one paragraph

Article in EJNMMI research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Trial
  2. Article
  3. Characterizing amyloid and tau positron emission tomography-based stages across the clinical continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Quantitative Measurement of Tau Burden in a Dual-Time-Window Dynamic PET Imaging Protocol with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. Article
  6. Article
  7. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  8. Article
  9. Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  10. Non-invasive quantification ofEJNMMI research · 2024
    Article
  11. Article
  12. Non-invasive quantification ofResearch square · 2023
    Article
  13. Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  14. Feasibility evaluation of middle-phaseQuantitative imaging in medicine and surgery · 2023
    Article
  15. Measurement of Cerebral Perfusion Indices from the Early Phase of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  16. Article
  17. Precision estimates of relative and absolute cerebral blood flow in Alzheimer's disease and cognitively normal individuals.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  18. Longitudinal Tau PET UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  19. Quantification of amyloid PET for future clinical use: a state-of-the-art review.European journal of nuclear medicine and molecular imaging · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fiona HeemanAmsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands. f.heeman@vumc.nl.ORCID http://orcid.org/0000-0001-7769-8329
Maqsood YaqubAmsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0001-6738-2742
Isadora Lopes AlvesAmsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands.
Kerstin HeurlingWallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, 405 30, Gothenburg, Sweden.ORCID http://orcid.org/0000-0001-8497-9612
Johannes BerkhofAmsterdam UMC, Vrije Universiteit Amsterdam, Epidemiology and Biostatistics, De Boelelaan, 1117, Amsterdam, Netherlands.
Juan Domingo GispertBarcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Carrer de Wellington, 30, 08005, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6155-0642
Santiago BullichLife Molecular Imaging GmbH, Tegeler Str. 7, 13353, Berlin, Germany.
Christopher FoleyGE Healthcare, Little Chalfont, Amersham, HP7 9NA, UK.ORCID http://orcid.org/0000-0002-7319-2539
Adriaan A LammertsmaAmsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0003-1237-2891
AMYPAD Consortium

Funding

Innovative Medicines Initiative 115952Ramón y Cajal RYC-2013-13054
6 · The paper itself

Abstract

backgroundA long dynamic scanning protocol may be required to accurately measure longitudinal changes in amyloid load. However, such a protocol results in a lower patient comfort and scanning efficiency compared to static scans. A compromise can be achieved by implementing dual-time-window protocols. This study aimed to optimize these protocols for quantitative [

methodsRate constants for subjects across the Alzheimer's disease spectrum (i.e., non-displaceable binding potential (BP

results[

conclusionsThe length of the interval inversely correlates with the accuracy of the BP

Indexed as

Alzheimer’s diseaseAmyloidFlorbetaben PETFlutemetamol PETQuantificationSimplified methods

Identifiers

PMID30919133
PMCPMC6437225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.